Skip to main content
Clinical Trials/NCT04255108
NCT04255108
Completed
Not Applicable

Validation of a Sensor for Non-invasive Measurement of Stroke Volume and Cardiac Output

Baxter Healthcare Corporation1 site in 1 country50 target enrollmentFebruary 19, 2020
ConditionsCardiac Failure

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiac Failure
Sponsor
Baxter Healthcare Corporation
Enrollment
50
Locations
1
Primary Endpoint
Accuracy of Stroke Volume
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

toSense, Inc. has developed a novel, non-invasive, body-worn sensor -CoVa Patch-that offers an alternative to invasive continuous cardiac output monitoring. To validate this new sensor's measurements of stroke volume and cardiac output, toSense, Inc. will conduct a study that compares its measurement performance to that from a pulmonary artery catheter using the thermodilution method.

Detailed Description

This in an introductory clinical study with cardiac ICU patients featuring CoVa Patch. This is a single site, non-blinded, non-randomized study. It will employ a retrospective analysis comparing the accuracy of SV and CO. The 'test sensor', CoVa Patch, which will measure SV and CO quasi-continuously and non-invasively, approximately every 5-30 minutes for a period of time lasting approximately 12-48 hours. These measurements will be compared to those from a 'reference device', which is the pulmonary arterial catheter. It uses an invasive technique called thermodilution that will be made approximately every 4 hours. Measurements between the test and reference devices will be compared in a retrospective analysis once the study has completed.

Registry
clinicaltrials.gov
Start Date
February 19, 2020
End Date
April 9, 2020
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male or female ≥ 18 years of age at Visit X.
  • Subject is a patient in the Cardiac ICU and meets the following criteria: pulmonary artery catheterization scheduled or completed.
  • Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
  • Subject is not pregnant at the time of consent

Exclusion Criteria

  • Pregnant in the study.
  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
  • Subject is unable or unwilling to wear electrode patches as required for a period between 6 to 48 hours.

Outcomes

Primary Outcomes

Accuracy of Stroke Volume

Time Frame: 4 Months

The primary objective of this study is to validate stroke volume (the amount of blood pumped by the left ventrical of the heart in one contraction) measurements made using CoVa Patch to those made using a pulmonary artery catheter and the thermodilution method. Thermodilution requires a pulmonary artery catheter and are calculated by a monitoring system based on temperature changes in the heart when a cooler solution is injected into the right atrium via the proximal port of a pulmonary artery catheter.

Accuracy of Cardiac Output

Time Frame: 4 Months

The secondary objective of this study is to validate cardiac output (the amount of blood the heart pumps per minute) measurements made using CoVa Patch to those made using a pulmonary artery catheter and the thermodilution method. Thermodilution requires a pulmonary artery catheter and are calculated by a monitoring system based on temperature changes in the heart when a cooler solution is injected into the right atrium via the proximal port of a pulmonary artery catheter.

Study Sites (1)

Loading locations...

Similar Trials